Aug 10, 2017

Name of listed company:   Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Osamu Nagayama
Inquiries to: Masahiko Uchida,
General Manager, Corporate Communications Dept.

Announcement of a Commencement of Arbitration against Chugai

Chugai Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo / Chairman & CEO: Osamu Nagayama, "Chugai") announces that an arbitration against Chugai has been commenced as follows.

  1. Description of the Arbitration
    i. Location of Arbitration etc.
    Location: The United Kingdom
    Governing Law: English law
    Date of the service of the Request for Arbitration: May 10, 2017
    Date of appointment of the Arbitrator: August 9, 2017
    ii. Parties Who Requested Arbitration
    Name: Medical Research Council and LifeArc (formerly, Medical Research Council Technology)
    Location: The United Kingdom
    iii. The Arbitration Claim
    Arbitration is a private and confidential dispute resolution procedure, however the parties have agreed to this disclosure. Sums are sought from Chugai for alleged breach of obligations under a collaboration agreement dated 15 August, 1990 in connection with the development of the humanized anti-human IL-6 receptor monoclonal antibody, ACTEMRA®. It is claimed that Chugai is obliged to pay royalties to the Claimants pursuant to the collaboration agreement.
  2. Prospects
    Chugai considers that the claims are without merit and Chugai will vigorously defend itself in the arbitration. At this moment, no change is expected to the financial prospects of Chugai.

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881

For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554

[ PDF 39KB]

To view PDF files,
you will need Adobe® Reader® which is available as a free download.